<DOC>
	<DOCNO>NCT03002103</DOCNO>
	<brief_summary>This prospective , multicenter , open-label , randomize , control trial test superiority EndoTAG®-1 combination paclitaxel gemcitabine versus paclitaxel combination gemcitabine . An independent data safety monitor board ( DSMB ) establish decide recommend dose ( RD ) EndoTAG®-1 , paclitaxel gemcitabine use throughout trial monitor patient ' safety treatment efficacy data</brief_summary>
	<brief_title>A Trial Evaluating Efficacy Safety EndoTAG®-1 Combination With Paclitaxel Gemcitabine Compared With Paclitaxel Gemcitabine First-line Therapy Patients With Visceral Metastatic Triple-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Gender : Female 2 . Age ≥ 18 year legal age provide inform consent accord local regulatory requirement . 3 . Metastatic TNBC confirm histologically certify local laboratory ( exist medical record confirmation acceptable patient safety runin stage ) use archival paraffinated material original surgery specimens later material , available . Results certify local laboratory must available allow randomization . Tumors consider negative ER PrR immunohistochemistry ( IHC ) ( &lt; 1 % positive tumor nucleus , per American Society Clinical Oncology/College American Pathologists [ ASCO/CAP ] guideline recommendation , Hammond et al 2010 ) negative HER2 IHC fluorescent chromogenic situ hybridization ( FISH CISH ) . Patients equivocal HER2 result IHC negativity status confirm FISH . 4 . Patients must prior adjuvant treatment either sequential concurrent anthracycline and/or taxanebased chemotherapy . Patients may receive neoadjuvant treatment prior adjuvant anthracycline and/or taxanebased chemotherapy well . 5 . Patients diseasefree interval ( DFI ) anthracycline and/or taxanebased adjuvant therapy ≥ 12 month . 6 . Patients must indicate treatment polychemotherapy visceral metastatic disease judge Investigator . 7 . At least one measurable nonmeasurable tumor lesion accord RECIST version 1.1 assessed Investigator ( local radiological image assessment ) . 8 . ECOG performance status 0 1 . 9 . Negative pregnancy test ( female childbearing potential ) . 10 . Willingness perform doublebarrier contraception study 6 month post chemotherapy treatment ( female childbearing potential ) . 11 . Signed informed consent . 1 . Prior firstline chemotherapy locally recurrent and/or metastatic breast cancer , include visceral disease . 2 . Brain metastasis/known progressive cerebral metastasis ( patient cerebral metastasis stable state successful surgical radiological treatment allow participate study ) . 3 . Major surgery &lt; 4 week prior enrollment . 4 . Cancer immunotherapy time . 5 . Severe pulmonary obstructive restrictive disease . 6 . Uncontrolled inflammatory disease ( autoimmune infectious ) . 7 . Clinically significant cardiac disease ( New York Heart Association [ NYHA ] stadium &gt; 2 ) . 8 . Results laboratory test ( hematology , coagulation , clinical chemistry ) outside specify limit : White blood cell ( WBC ) count ≤ 3 × 109/L Absolute neutrophil count ( ANC ) ≤ 1.5 × 109/L Platelets ≤ 100 × 109/L Hemoglobin ( Hb ) ≤ 9.0 g/dL ( ≤ 5.6 mmol/L ) Partial thromboplastin time/international normalize ratio ( PTT/INR ) &gt; 1.5 × upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 × ULN ( &gt; 5 × ULN presence liver metastasis ) Alkaline phosphatase ( AP ) &gt; 2 × ULN ( &gt; 5 × ULN presence liver metastasis ) Total bilirubin &gt; 1.5 × ULN ( &gt; 2.5 × ULN presence liver metastasis ) 9 . Pregnancy nursing status . 10 . Known positive human immunodeficiency virus ( HIV ) infection medical history . 11 . Peripheral neuropathy associate prior taxane therapy recover grade 0 1 . 12 . Known hypersensitivity component EndoTAG®1 , standard paclitaxel and/or gemcitabine formulation . 13 . History malignancy breast cancer &lt; 5 year prior enrollment , except skin cancer ( i.e. , basal squamous cell carcinoma ) treat locally . 14 . History active significant neurological disorder psychiatric disorder would prohibit understanding give informed consent , would interfere clinical radiological evaluation central nervous system trial . 15 . Concurrent treatment experimental product . Participation another clinical trial investigational product within 30 day prior study entry . 16 . Positive test hepatitis B ( hepatitis B virus surface antigen [ HBsAg ] positive ; HBsAg negative antihepatitis B virus core [ HBc ] antibody positive HBV DNA positive ) hepatitis C ( anti hepatitis C virus [ HCV ] antibody positive ) . Patients antiHCV antibody positive also judge eligible HCV RNA detection show negative result .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>